医药行业数字化转型加速，医药供应链领域正经历结构性变革，竞争转向科技赋能与模式创新。作为A 股创业板医药供应链龙头，国内首家上市的医药产业 互联网 企业 药易购 （股票代码：300937）立足行 业趋势，在升级核心医药供应链业务的同时，持续加码创新业务，通过科技赋能构筑长期竞争壁垒，其 前瞻性布局不仅契合行业发展方向，更具备极强的资本市场长期布局价值。 我国医药行业正处于高质量发展转型期，2026年AI医疗拐点确立，行业展望指出"AI赋能+基本面反 转"将成为核心增长引擎，这为医药供应链企业的创新升级提供了广阔空间。"十四五"期间药品供应链 市场规模持续扩容，2024年销售额达2.95万亿元，其 中药 品零售市场6500亿元。商务部等9部门印发相 关意见，推动药品零售行业数字化、规范化发展，为药易购创新布局提供了重要政策支撑，也进一步打 开了药易购等公司新业务的资本想象空间。 随着医药科技进步、政策完善以及AI医疗拐点确立，行业集中度将持续提升，具备科技优势、新赛道 布局前瞻的企业将获得更大发展空间，也将成为资本市场的核心关注标的。药易购的创新布局精准契合 行业方向，新赛道多点开花，长期价值增长确定性强，有望 ...

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. for the first half of 2025, indicating a decline in revenue and net profit, while outlining the company's focus on expanding its healthcare ecosystem and digital transformation efforts [1][3][4]. Financial Performance - The company's revenue for the reporting period was approximately CNY 2.16 billion, a decrease of 3.06% compared to the same period last year [3]. - The net profit attributable to shareholders was a loss of CNY 7.61 million, representing a decline of 162.95% year-on-year [3]. - The basic earnings per share were reported at -0.08 CNY, down 161.54% from the previous year [3]. - Total assets increased by 1.91% to approximately CNY 1.75 billion compared to the end of the previous year [3]. Business Strategy - The company has been focusing on the outpatient pharmaceutical distribution market since its establishment in 2007, leveraging its technological capabilities and infrastructure to build a comprehensive health ecosystem [4][5]. - The strategy includes expanding upstream in the supply chain through product diversification, brand operation, and mergers and acquisitions to enhance pricing power [5][6]. - The company aims to develop a "golden product" ecosystem in specific disease areas by investing in ethnic medicine, traditional Chinese medicine, and medical devices [5][6][7]. Digital Transformation - The company is enhancing its digital capabilities by investing in AI-driven retail systems and establishing a comprehensive supply chain management platform [6][12]. - It has developed a digital medicine distribution business that includes B2B e-commerce and retail operations, covering over 20,000 pharmaceutical products [12][14]. - The company is also focusing on building a smart retail ecosystem that integrates online and offline channels to improve customer engagement and service delivery [15][20]. Brand Development - The company has established several key brands, including "Weige" and "Youshili," which have gained significant market traction in their respective categories [10][16]. - It is actively promoting traditional Chinese medicine brands and has secured exclusive distribution rights for several innovative products [7][8][10]. - The company is leveraging content marketing and digital platforms to enhance brand visibility and consumer engagement [10][17]. Investment and Partnerships - The company has formed strategic partnerships with various pharmaceutical manufacturers and research organizations to enhance its product offerings and market reach [7][8][19]. - It is also investing in health technology and wearable medical devices to support chronic disease management and health monitoring [9][11]. - The establishment of the "Jiansu Yigou Fund" aims to invest in high-quality pharmaceutical products and innovative sales channels, creating a synergistic effect with the company's existing operations [20].